Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

TCR therapy and vascular research map barriers in ovarian cancer treatment

December 01, 2025

Researchers outlined both clinical obstacles for T‑cell receptor (TCR) therapies in ovarian cancer and new insights into VEGF‑driven vascular pathways that fuel tumor growth. The TCR review...

RNAi candidate cuts HBV markers — path to functional cure

December 01, 2025

Researchers published a Nature Communications study demonstrating an RNA interference (RNAi) therapeutic that substantially reduces hepatitis B virus (HBV) markers and supports the prospect of a...

Menin inhibitors: breakthrough targeted option for KMT2A leukemia

December 01, 2025

New research and clinical interest are converging on menin inhibitors as a targeted strategy for KMT2A-rearranged acute leukemias. Studies show menin blockade disrupts the leukemogenic program...

Endpoint dilution SAA quantifies α-syn seeds — diagnostic advance

December 01, 2025

Researchers unveiled an endpoint dilution seed amplification assay (SAA) that quantifies cerebrospinal fluid α-synuclein seeds with improved precision, delivering a more granular biomarker for...

Engineered ACE2 decoy neutralizes multi-variant SARS-CoV-2

December 01, 2025

A study in the Journal of Biomedical Science reported an engineered ACE2 decoy receptor that neutralizes mutant and escape variants of SARS-CoV-2. The decoy binds spike protein across divergent...

FDA biosimilar push runs into patent-office resistance

December 01, 2025

The FDA announced plans to streamline biosimilar approval pathways to mimic generic regulation, promising lower development costs and faster market entry. Industry leaders touted potential savings...

mTORC1 in ILC2s: neuro-immune axis drives allergic lung inflammation

December 01, 2025

A Nature Communications 2025 study identified mTORC1 signaling in group 2 innate lymphoid cells (ILC2s) as a central node linking neuronal cues to allergic lung inflammation. The authors used...

AML survival pathways: THRAP3 and RPPH1 drive therapy resistance

December 01, 2025

Two mechanistic studies chart distinct molecular drivers that enable acute myeloid leukemia (AML) cells to evade cell death and sustain aggressive disease. One report identifies THRAP3 as a...

TCR therapy in ovarian cancer: delivery and specificity challenges persist

December 01, 2025

A global research synthesis highlights ongoing hurdles for T-cell receptor (TCR) therapies in ovarian cancer, including tumor heterogeneity, on-target off-tumor toxicity, and insufficient...

Fucosidase dependency: new target for rotavirus and norovirus replication

December 01, 2025

Researchers discovered that both rotavirus and norovirus replication depend on host fucosidase activity, revealing a conserved glycan-processing vulnerability in two major gastrointestinal...

Sepsis outcomes tied to IgG levels and ferroptosis mechanisms

December 01, 2025

Two studies advance the clinical and mechanistic understanding of sepsis. A multicenter analysis led by Hu et al. found serum IgG levels predict sepsis outcomes and may identify patients who...

RNAi for HBV: Nature Communications flags a possible functional cure

December 01, 2025

Researchers published a Nature Communications paper reporting an RNA interference (RNAi) therapeutic that significantly reduces hepatitis B virus markers and advances toward a functional cure. The...

Menin inhibitors: targeted therapy advances for KMT2A‑rearranged leukemia

December 01, 2025

Researchers and clinical teams reported that menin inhibitors continue to emerge as the leading targeted approach for KMT2A‑rearranged acute leukemias, a historically treatment‑resistant subset....

ACE2 decoy receptor neutralizes SARS‑CoV‑2 variants — blocking mutants too

December 01, 2025

A team led by Lin et al. published work in the Journal of Biomedical Science describing an engineered ACE2 decoy receptor that neutralizes multiple mutant SARS‑CoV‑2 strains. The decoy binds...

Jumbo phage targets MBL Pseudomonas — therapeutic candidate for resistant infections

December 01, 2025

Paranos and colleagues reported discovery and characterization of a jumbo bacteriophage active against metallo‑β‑lactamase (MBL)–producing Pseudomonas aeruginosa strains. The study describes host...

α‑Synuclein seed quantification: new CSF assay sharpens Parkinson’s diagnostics

December 01, 2025

Researchers unveiled an endpoint dilution seed amplification assay (SAA) that quantifies α‑synuclein seeding activity in cerebrospinal fluid with higher precision. The team reported improved...

Renal IGFBP7: a driver of diabetic kidney disease identified

December 01, 2025

A Nature Communications study by Yu, Hu, Wang and colleagues identified renal insulin‑like growth factor binding protein 7 (IGFBP7) as a molecular driver of progressive diabetic kidney disease...

Sepsis biology splits: ferroptosis role and IgG as a prognostic biomarker

December 01, 2025

Two complementary studies reframed sepsis pathophysiology and prognostication. One team identified ferroptosis as a central contributor to sepsis development, mapping molecular triggers and...

Ultrasound‑triggered PANoptosis: piezoelectric nanocatalysts provoke tumor collapse

December 01, 2025

Xu et al. published a study in Military Medicine Research demonstrating ultrasound‑activated piezoelectric nanocatalysts that induce PANoptosis—a combined program of pyroptosis, apoptosis and...

AML molecular drivers: THRAP3 and RPPH1 link to ferroptosis resistance and inflammation

December 01, 2025

Two studies uncovered distinct molecular mechanisms that sustain acute myeloid leukemia (AML) survival and progression. One report identified THRAP3 as a promoter of ferroptosis resistance through...